317 related articles for article (PubMed ID: 19077395)
41. The performance of prostate specific antigen, prostate specific antigen density and transition zone density in the era of extended biopsy schemes.
Elliott CS; Shinghal R; Presti JC
J Urol; 2008 May; 179(5):1756-61; discussion 1761. PubMed ID: 18343425
[TBL] [Abstract][Full Text] [Related]
42. A clinicopathologic study of preoperative and postoperative findings with minute Gleason 3+3=6 cancer at radical prostatectomy.
Osunkoya AO; Carter HB; Epstein JI
Urology; 2008 Sep; 72(3):638-40. PubMed ID: 18400278
[TBL] [Abstract][Full Text] [Related]
43. Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease.
Helfand BT; Mongiu AK; Kan D; Kim DY; Loeb S; Roehl KA; Meeks JJ; Smith ND; Catalona WJ
BJU Int; 2009 Aug; 104(3):304-9. PubMed ID: 19239451
[TBL] [Abstract][Full Text] [Related]
44. Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy.
Crawford ED; Wilson SS; Torkko KC; Hirano D; Stewart JS; Brammell C; Wilson RS; Kawata N; Sullivan H; Lucia MS; Werahera PN
BJU Int; 2005 Nov; 96(7):999-1004. PubMed ID: 16225516
[TBL] [Abstract][Full Text] [Related]
45. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
BJU Int; 2009 Jun; 103(11):1472-7. PubMed ID: 19154509
[TBL] [Abstract][Full Text] [Related]
46. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
Gosselaar C; Roobol MJ; Roemeling S; Schröder FH
Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
[TBL] [Abstract][Full Text] [Related]
47. Diffuse adenosis of the peripheral zone in prostate needle biopsy and prostatectomy specimens.
Lotan TL; Epstein JI
Am J Surg Pathol; 2008 Sep; 32(9):1360-6. PubMed ID: 18670353
[TBL] [Abstract][Full Text] [Related]
48. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease.
Dall'era MA; Hosang N; Konety B; Cowan JE; Carroll PR
J Urol; 2009 Apr; 181(4):1622-7; discussion 1627. PubMed ID: 19230923
[TBL] [Abstract][Full Text] [Related]
49. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study.
Kvåle R; Møller B; Wahlqvist R; Fosså SD; Berner A; Busch C; Kyrdalen AE; Svindland A; Viset T; Halvorsen OJ
BJU Int; 2009 Jun; 103(12):1647-54. PubMed ID: 19154461
[TBL] [Abstract][Full Text] [Related]
50. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
[TBL] [Abstract][Full Text] [Related]
51. [Cancer of the prostate stage T1. Incidental carcinoma. Review of the literature and an appraisal of the classification].
Leisinger HJ
Ann Urol (Paris); 1994; 28(4):229-34. PubMed ID: 7979213
[TBL] [Abstract][Full Text] [Related]
52. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era.
Jones JS; Follis HW; Johnson JR
Prostate Cancer Prostatic Dis; 2009; 12(1):57-60. PubMed ID: 18379587
[TBL] [Abstract][Full Text] [Related]
53. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
54. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
Ploussard G; Dubosq F; Boublil V; Allory Y; de la Taille A; Vordos D; Hoznek A; Abbou CC; Salomon L
J Urol; 2009 Oct; 182(4):1342-9. PubMed ID: 19683310
[TBL] [Abstract][Full Text] [Related]
55. Appropriate patient selection in the focal treatment of prostate cancer: the role of transperineal 3-dimensional pathologic mapping of the prostate--a 4-year experience.
Barzell WE; Melamed MR
Urology; 2007 Dec; 70(6 Suppl):27-35. PubMed ID: 18194708
[TBL] [Abstract][Full Text] [Related]
56. Prebiopsy PSA velocity not reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume after TTMB.
Bittner N; Merrick GS; Andreini H; Taubenslag W; Allen ZA; Butler WM; Anderson RL; Adamovich E; Wallner KE
Urology; 2009 Jul; 74(1):171-6. PubMed ID: 19232691
[TBL] [Abstract][Full Text] [Related]
57. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
58. [Analysis of anatomopathological results of radical prostatectomy specimen of patients who answer to criteria for active surveillance of prostate cancer].
Azancot V; Peyromaure M; Xylinas E; Descazeaud A; Cornud F; Vieillefond A; Saighi D; Amsellem-Ouazana D; Debré B; Zerbib M
Prog Urol; 2009 Oct; 19(9):619-23. PubMed ID: 19800552
[TBL] [Abstract][Full Text] [Related]
59. [Clinical study of stage a prostatic cancer detected incidentally by transurethral resection of the prostate].
Nakanishi S; Gotou T; Sawada A; Shibasaki N; Ishitoya T; Okumura K
Hinyokika Kiyo; 2009 Jan; 55(1):5-8. PubMed ID: 19227204
[TBL] [Abstract][Full Text] [Related]
60. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy.
Haese A; de la Taille A; van Poppel H; Marberger M; Stenzl A; Mulders PF; Huland H; Abbou CC; Remzi M; Tinzl M; Feyerabend S; Stillebroer AB; van Gils MP; Schalken JA
Eur Urol; 2008 Nov; 54(5):1081-8. PubMed ID: 18602209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
